Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Free Report) fell 3.1% on Thursday. The stock traded as low as $0.31 and last traded at $0.31. Approximately 100 shares traded hands during trading, a decline of 100% from the average daily volume of 27,473 shares. The stock had previously closed at $0.32.
Anebulo Pharmaceuticals Stock Performance
The stock has a fifty day simple moving average of $0.33 and a two-hundred day simple moving average of $0.43. The stock has a market cap of $12.64 million, a price-to-earnings ratio of -1.63 and a beta of -1.88.
Anebulo Pharmaceuticals Company Profile
Anebulo Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and related medical emergencies. The company’s work is aimed at addressing the effects of cannabis and synthetic cannabinoids, including situations in which patients require urgent medical care.
Anebulo’s lead investigational product, ANEB-001, is an orally administered antagonist of the cannabinoid type 1 (CB1) receptor. The company is developing ANEB-001 to rapidly reverse the effects of cannabinoid intoxication, with potential applications in emergency and acute-care settings.
Further Reading
- Five stocks we like better than Anebulo Pharmaceuticals
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
